Global Pleural Effusion Treatment Market Report and Forecast 2024-2032

Global Pleural Effusion Treatment Market Outlook

The global pleural effusion treatment market is expected to grow at a CAGR of 4.90% between 2024 and 2032. Key market drivers are rise in cases of pleural effusion, increasing treatment facilities, and spreading awareness.

Key Trends in the Market

Pleural effusion, also known as ‘water on the lungs’ is an abnormal lung condition in which excess fluid builds up outside the lungs between the layers of pleura. They are usually caused by conditions such as pulmonary embolisms, congestive heart failure, pneumonia, and cancer. Some of the common pleural effusion treatments include pleurodesis, drainage catheter placement, surgery, and therapeutic thoracentesis. 

• Occurrences of pleural effusion are rapidly increasing because of growing prevalence of lung tumours, further fuelled by cigarette smoking. Other conditions such as blood vessel blockage, lung injuries, and congestive heart failures are also increasing the cases for pleural effusion increasing the demand for pleural effusion treatment.

• Major market players are carrying out research and development activities, launching new products to treat pleural effusions more easily and effectively.

• Increased awareness regarding pleural effusion and its symptoms is encouraging patients to seek out treatment earlier, supplementing the demand for the pleural effusion treatment market.

Market Analysis

Based on disease type, the market can be bifurcated into transudate effusion and exudate effusion. On the basis of treatment, the market is divided into tube thoracostomy (chest tube), pleurodesis, thoracentesis, pleurodesis, thoracentesis, pleural decortication, and pleural drain, among others. Based on end use, the market is categorised into hospitals, specialised clinics, and ambulatory surgical centres, among others. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global pleural effusion treatment market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.

• B. Braun Melsungen AG

• Becton, Dickinson, and Company

• Biometrix

• Rocket Medical plc

• ICU Medical Inc.

• Others

Market Share by Disease Type

Transudative effusion disease type has accounted for a large share in the pleural effusion treatment market because of the increasing prevalence of congestive heart failures, cirrhosis, and kidney failure that can lead to transudative effusion. Transudative is caused by a hydrostatic imbalance with a build-up of watery fluid outside the lungs. Increasing prevalence of such conditions are likely to result in an increase in transudative effusion cases. 

Exudate effusions are caused by increased capillary permeability that leads to leakage of cell, protein, and other serum constituent. Conditions that cause exudative effusion are tuberculosis, pneumonia, or diseases causing pleuro-renal syndromes. Demand for pleural effusion treatment for exudate effusions tends to vary depending upon region, and the prevalence of causing conditions. 

Market Share by Region

North America accounted for a large share in the pleural effusion treatment market because of rising prevalence of the pleural effusion and rising cases of heart related diseases in the North American region. Furthermore, rising healthcare expenditure, increase in geriatric populations, and robust healthcare infrastructure in countries such as the United States have supported the growth of the region in the overall market. 

Asia Pacific is also expected to observe a significant growth in the market for pleural effusion treatment owing to increasing cases of respiratory disorder and lung cancer. With advancements in healthcare technology used in the region, multiple treatment options for pleural effusion are becoming increasingly accessible in the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Biometrix was founded in 1986 and is based in Yerushalayim, Israel. It is a medical device company that develops and manufactures premium quality medical devices in order to meet the medical demands of various critical care procedures in various industries such as biotechnology, pharmaceuticals, and medical device industry. 

Rocket Medical plc is a medical equipment manufacturing company that designs and manufactures single use medical devices for clinical use in various areas such as diagnostic machines, reproductive medicines, pulmonary therapy, obstetrics, and ascites drainage. It has its headquarter in Washington in the United Kingdom and was founded in 1964. 

ICU Medical Inc. was established in 1984 and is headquartered in California, United States. It designs and manufactures medical technologies and distributes them globally for oncology, critical care, and vascular therapy. They believe in connecting healthcare providers and patients with the help of safe, life enhancing, and life saving devices.   

Other market players include B. Braun Melsungen AG, and Becton, Dickinson, and Company, among others.

Key Highlights of the Report